Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MGNX with free AI briefings, catalyst countdowns, and dilution alerts.

MGNX · MACROGENICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$327M Cash, Pro Forma
25.6mo Cash Runway
Follow MGNX by email Get an email when MGNX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MGNX, unsubscribe in one click. Privacy

📣 What MGNX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tebotelimab Gastric Cancer Phase 2/3 · NCT04082364 Completed
Teplizumab Curtailed Herold Regimen Type 1 Diabetes Mellitus Phase 3 · NCT00920582 Terminated
Vobramitamab Duocarmazine (MGC018) Castration-Resistant Prostatic Cancer Phase 2 · NCT05551117 Terminated
MGAWN1 West Nile Neuroinvasive Disease Phase 2 · NCT00927953 Terminated
Anti-gpA33/CD3 Monoclonal Antibody MGD007 Colorectal Cancer Metastatic Phase 1/2 · NCT03531632 Completed
Monoclonal Antibody RAV12 Pancreatic Cancer Phase 2 · NCT00625586 Terminated
Flotetuzumab AML Phase 1/2 · NCT02152956 Terminated
Flotetuzumab 300 ng/kg/day, continuous… AML Phase 1/2 · NCT02152956 Terminated
Izeltabart Tapatansine (IMGC936) Advanced Solid Tumor Phase 1/2 · NCT04622774 Completed
Lorigerlimab Platinum-resistant Ovarian Cancer Phase 2 · NCT06730347 Recruiting
Vobramitamab Tavatecan (MGC026) Advanced Solid Tumor Phase 1 · NCT06242470 Recruiting
Obrindatamab (MGD009) Mesothelioma Phase 1 · NCT02628535 Terminated
Enoblituzumab (MGA271) Melanoma Phase 1 · NCT02475213 Completed
Hepatitis A Vaccine Healthy Subjects Phase 1 · NCT02376036 Completed
Anti-ADAM9/Exatecan Antibody-drug Conjugate… Advanced Solid Tumors Phase 1 · NCT06723236 Recruiting
MGC030 Urothelial Cancer Phase 1 · NCT07822399 Recruiting

Also used in these trials (approved or third-party drugs, not MGNX's own candidates): Retifanlimab, Margetuximab, Trastuzumab, Teplizumab, Capecitabine, Tucatinib, Paclitaxel, Pembrolizumab, Pertuzumab, Prednisone, Regorafenib, Ruxolitinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MGNX had $173.3M in cash and short-term investments on its Jun 30, 2026 balance sheet. Including the cash events since then, it holds about $327M pro forma, before operating spending after that date:

It burns about $38.3M/quarter from operations, an estimated runway of 25.6 months from Jun 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGNX files for a raise →

👥 Who Owns MGNX

Insiders 2.6% Institutions (184 holders) 79% Public and other holders 18.4%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13G, 5%+) 6,000,000 9.39% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 4,503,913 7.05% 2026-06-30
Scott Koenig
Director · +41,582 options
Insider 867,240 1.36% 2026-02-15
James Karrels
SVP and CFO · +175,000 options
Insider 206,037 0.32% 2026-02-12
Ezio Bonvini
Sr VP, Research & CSO · +298,750 options
Insider 193,799 0.30% 2026-10-06
William K Heiden
Director · +47,750 options
Insider 114,750 0.18% 2026-05-18
Eric Blasius Risser
President and CEO, Director · +1.25M options
Insider 77,169 0.12% 2026-02-12
Edward Hurwitz
Director · +47,750 options
Insider 47,824 0.07% 2026-05-18
Thomas Spitznagel
Sr VP, Technical Ops · +205,000 options
Insider 38,543 0.06% 2026-02-12
Jay Philip Siegel
Director
Insider 14,750 0.02% 2026-05-18
Federica F. O'Brien
Director · +112,711 options
Insider 14,750 0.02% 2026-05-18
David C Stump
Director · +47,750 options
Insider 14,750 0.02% 2026-05-18

Share count 63,908,946 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MGNX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGNX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.